BioSpace News Archive

Ampersand Capital Partners announced that it has completed the sale of Nexcelom Bioscience, one of its portfolio companies and a leading provider of automated cell counting solutions, to PerkinElmer for $260 million in cash.

InnoCare, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced that China’s National Medical Products Administration has approved the initiation of a Phase I clinical trial of ICP-033, the Company’s novel RTK inhibitor and its sixth innovative drug to enter clinical development.

European Commission Decision expected Q3 2021 Temporary Authorization for Use (ATU) Granted in France to Allow Access and Reimbursement of Vosoritide to Begin Immediately

VistaGen Therapeutics, Inc . today announced that it will host a corporate update conference call on Tuesday, June 29, 2021 at 2:00 pm Pacific Time (5:00 pm Eastern Time) to discuss its financial and operating results for fiscal year ended March 31, 2021.

Centene Corporation (NYSE: CNC) today issued a reminder that it will release its 2021 second quarter financial results at approximately 6 a.m. (Eastern Time) on Tuesday , July 27, 2021, and host a conference call afterwards at approximately 8:30 a.m. (Eastern Time) to review the results.

The Cancer Research Institute announced that is has launched its first-ever Spanish-language information hub to connect Hispanic patients and caregivers with the latest cancer immunotherapy research and treatment options.

I-Mab today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a phase 1b trial of felzartamab, a CD38 antibody, in patients with systemic lupus erythematosus (SLE).

Happiness Biotech Group Limited announced today that it has entered into a securities purchase agreement with certain non-U.S. strategic investors for a registered direct placement of approximately $2.16 million.

Curis, Inc. today announced that it will be added to the Russell 2000®, 3000® and Microcap® indexes at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 4, 2021.

Acurx Pharmaceuticals, Inc. today announced the pricing of an underwritten initial public offering of 2,500,000 newly-issued shares of its common stock at a price of $6.00 per share.